What is Turn Therapeutics Inc. Common Stock?
, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.
TTRX · Verdict
Limited reward · moderate risk
TTRX stands out on volatility and balance sheet, but watch the cash flow signal.
Based on 88% data coverage
TTRX · Verdict
Top decile vs peers
Current ratio 1.55
Weak vs peers
-2325% return on equity
Earnings -22.9% CAGR
Model-based scoring. For information only — not financial advice.
, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 106.00M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.